公司资料
Aclarion 股价、新闻与催化剂
- 股票代码:
- ACON
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.71 USD (+0.74%)
收盘价
最后更新: 2026年8月21日
8.62M USD
市值
股价为何变动
Following the latest company update, “Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site”, ACON closed down 2.89% at $2.69 on Aug 20, 2026. The move occurred in the trading session associated with this clinical readout update.
公司概览
Chronic Low-Back-Pain Diagnostics
Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain. Its approach combines magnetic resonance spectroscopy, biochemical biomarkers, signal processing and augmented-intelligence algorithms.
Nociscan Platform
Nociscan is a software-as-a-service platform that analyzes disc chemistry noninvasively and classifies discs as more likely painful or nonpainful. Physicians use the information alongside imaging and other diagnostic tools when selecting treatment targets.
Evidence and Reimbursement Strategy
Aclarion is supporting Nociscan with multiple clinical and real-world evidence studies. The evidence program is intended to demonstrate treatment-selection value and establish commercial-insurance coverage pathways.
未来催化剂
- Preliminary internal CLARITY trial readout expected in the second half of 2026.
- Public disclosure of early interim CLARITY results anticipated in the fourth quarter of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。